New stock to watch: FCSC.OB (Fibrocell Science, Inc.)
PDUFA date on 1/4/2010. Potential price mover in anticipation.
Advisory Committee results (from company PR):
EXTON, Pa., October 9, 2009 - Fibrocell Science, Inc. (OTCBB: FCSC) announced today that the U.S. Food and Drug Administration's (FDA) Cellular, Tissue and Gene Therapies Advisory Committee reviewed azfibrocel-T, an autologous cell therapy being investigated for the treatment of moderate to severe nasolabial fold wrinkles in adults. The committee voted 11 yes to 3 no that the data presented on azfibrocel-T demonstrated efficacy, and 6 yes to 8 no that the data demonstrated safety, both for the proposed indication. The FDA is currently evaluating the USAN name, azfibrocel-T, and a proposed brand name, LavivTM.
www.fibrocellscience.com
Do your OWN DD before investing. I am NOT an analyst, just an individual investor.
GLTA.
Visit my biotech investing board!: investorshub.advfn.com/boards/board.aspx?board_id=16653
GLTA.
